National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 10) (Cth)

PB 110 of 2021

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 10)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated               28 October 2021

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Contents

1......... Name............................................................................................................................... 1

2......... Commencement............................................................................................................... 1

3......... Authority......................................................................................................................... 1

4......... Schedules......................................................................................................................... 1

Schedule 1—Amendments  2

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015).   2

1. Name

(1)This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 10).

(2)This Instrument may also be cited as PB 110 of 2021.

1. Commencement

(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 November 2021	1 November 2021

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1. Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4        Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

1. Schedule 1, after entry for Brivaracetam in the form Tablet 100 mg

insert:

Budesonide with glycopyrronium and formoterol Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses 20 1 5

1. Schedule 1, after entry for Dapsone in the form Tablet 100 mg

insert:

Darolutamide Tablet 300 mg 20 112 5

1. Schedule 1, omit entry for Metformin with glibenclamide

1. Schedule 1, entry for Olaparib

omit:

Capsule 50 mg 20 448 5

1. Schedule 1, entry for Phenoxybenzamine

omit:

Capsule containing 10 mg phenoxybenzamine hydrochloride 20 100 5

1. Schedule 1, entry for Pindolol

omit:

Tablet 5 mg (USP) 20 100 5

1. Schedule 1, omit entry for Sucralfate

1. Schedule 1, entry for Tamoxifen

omit:

Tablet 10 mg (as citrate) 20 60 5

1. Schedule 1, entry for Testosterone

omit:

Transdermal patches 12.2 mg, 60 20 1 5

1. Schedule 1, entry for Verapamil

omit:

Tablet containing verapamil hydrochloride 40 mg 20 100 5